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A B S T R A C T
Recently we established a novel aﬃnity puriﬁcation method for calpain by exploiting the speciﬁc and reversible
binding properties of its intrinsically disordered protein inhibitor, calpastatin. The immobilization strategy relied
on the strength and speciﬁcity of the biotin - streptavidin interaction. Here, we report an improved and opti-
mized method that even enables the general applicability of in vivo biotinylated (intrinsically disordered) pro-
teins in any aﬃnity capture strategy. Since in vitro chemical biotinylation is only accomplished with reagents
that lack exact site speciﬁcity, it can not only cause sample heterogeneity but it can also hamper the functionality
of the biotinylated molecules. Therefore, we have developed a recombinant expression protocol to produce in
vivo biotinylated human calpastatin domain 1 (hCSD1) in Escherichia coli. We have experimentally veriﬁed that
the biotinylated polypeptide tag is compatible with the intrinsically disordered state of hCSD1 and that it does
not inﬂuence the functional properties of this intrinsically disordered protein (IDP). The in vivo biotinylated
hCSD1 was then used without the need of any prepuriﬁcation step prior to the aﬃnity capturing of its substrate,
human m-calpain. This leads to a simpliﬁed puriﬁcation strategy that allows capturing the calpain eﬃciently
from a complex biological mixture with only a single chromatogaphic step and in a considerably reduced
timeframe. Our approach is generally applicable through the in vivo biotinylation of any IDP of interest, and its
practical implementation will showcase the power to exploit the properties of IDPs in aﬃnity capture strategies.
1. Introduction
The structural and biophysical characterization of proteins pri-
marily relies on substantial amounts of recombinantly expressed pro-
tein material that is repeatedly produced to enable various experi-
mental studies. Therefore, eﬃcient protein production and puriﬁcation
is often a bottleneck in the pipeline of ambitious structural biology and
drug development projects [1]. Calpains (EC 3.4.22.53) are such a class
of diﬃcult to purify proteases [2,3]. Mammalian calpains play an im-
portant biotechnological role in the post-mortem tenderization of meat
[4], while the human variants are involved in pathogenesis of Alzhei-
mer's disease, cancer and diabetes [1,5]. The activity of these in-
tracellular calcium-dependent proteases is controlled by a speciﬁc en-
dogenous inhibitor, called calpastatin [6].
Recently, we have reported a novel aﬃnity puriﬁcation protocol
whereby we exploit the binding speciﬁcity and aﬃnity of the in-
trinsically disordered protein (IDP) human calpastatin domain 1
(hCSD1) to purify its target protein, human m-calpain [7]. Upon further
considering the advantage of biotin-based immobilization, we have
explored the feasibility of using in vivo biotinylation for a simpliﬁed and
improved high-aﬃnity one-step puriﬁcation. Particularly, the re-
producibility and heterogeneity of the in vitro chemical biotinylation
can be a limiting factor in the functionality of the capturing agent in the
aﬃnity chromatography. To this end, we have developed a BirA pro-
tein-biotin ligase (EC 6.3.4.15) co-expression strategy in Escherichia coli
for the recombinant production of an avi-tagged hCSD1 construct. The
AviTag™ (also known as biotin acceptor peptide, BAP-tag) is a 15 re-
sidues-long sequence (GLNDIFEAQKIEWHE) that is speciﬁcally re-
cognized by the biotin ligase BirA [8]. BirA adds D-biotin covalently to
this polypeptide tag via a biotinyl 5′-adenylate intermediate that
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ultimately results in the formation of an amide-linkage between the
carboxyl group of biotin and the epsilon-amino group of the modiﬁed
lysine [9]. Interestingly, we wish to exploit the fact that only a single
endogenous protein in E. coli has been reported to become biotinylated
by BirA [10]. This is the biotin carboxyl carrier protein (BCCP; UniProt
P0ABD8), which is a 156 residues-long protein. While recombinantly
expressed IDPs can be puriﬁed easily upon boiling the resuspended
bacterial pellet [7,11], we anticipate that the well-folded BCCP will
precipitate upon boiling the bacterial lysate.
Here, we show that the avi-tagged hCSD1 construct can be bioti-
nylated eﬃciently and speciﬁcally in E. coli. We also show that the avi-
tag is fully compatible with the intrinsically disordered nature of hCSD1
and hence has no negative eﬀect on its interaction with m-calpain. This
in vivo biotinylated hCSD1 is then used to eﬃciently purify its natural
binding partner in a single chromatographic step.
2. Materials and methods
2.1. Bacterial strains and plasmid transformation
As recombinant expression vector we used the pET22b plasmid
(Novagen) whereby the hCSD1 gene (residues 137 - 277 of the human
calpastatin (UniProt ID P20810)) is fused with an N-terminal AviTag™
sequence, extended with a stop codon and cloned within the NdeI and
EcoRI restriction sites through a commercial gene synthesis service
(Genscript). This plasmid (which we designated pAvihCSD1) contains
an ampicillin resistant gene and an inducible T7 promoter system. For
the co-expression of the BirA protein and the in vivo biotinylation ex-
periments, we employed two commercially available bacterial strains:
E. coli AVB100 and AVB101 (Avidity LLC). AVB100 is an E. coli K12
strain [MC1061 araD139 δ(ara-leu)7696 δ(lac)l74 galU galK hsdR2(rK-
mK+) mcrB1 rpsL(StrR)], whereby the birA gene is integrated into the
bacterial chromosome. In this strain the BirA expression can be induced
with arabinose. The AVB101 is an E. coli B strain (hsdR, lon11, sulA1)
that contains pBirAcm, an IPTG inducible plasmid comprising the birA
gene and a chloramphenicol-resistance gene.
Since the E. coli K12 strain (AVB100) does not contain the T7 RNA
polymerase system we resorted to the pT7pol23 and pT7pol26 plasmids
(generously provided by Dr Henri De Greve), which both contain a
kanamycin-resistance gene, to express T7 polymerase under heat- and
IPTG-inducible promoter, respectively [12]. For the co-transformation
of the plasmids, the pAvihCSD1 and each of the pT7 plasmids were
transformed in two separate steps into chemically competent E. coli
AVB100 and AVB101 cells. In ﬁrst instance, 20 ng of the pT7pol23 or
pT7pol26 was transformed into the above-mentioned E. coli cells by the
heat shock method. The successful transformants were selected using
Lysogeny broth (LB)-agar plates that were supplemented with 50 μg/mL
kanamycin for the AVB100 strain or 10 μg/mL chloramphenicol and
50 μg/mL kanamycin for the AVB101 strain. A single colony of those
transformants was used to generate chemically competent cells for the
subsequent transformation of the pAvihCSD1 plasmid. The ﬁnal trans-
formants were selected using the above LB-agar plate supplemented
with 100 μg/mL ampicillin.
The untagged version of hCSD1 is produced in E. coli BL21-AI, while
the heterodimeric C105A mutant of human m-calpain was produced in
BL21(DE3), as reported previously for both proteins [7].
2.2. Recombinant protein production and in vivo biotinylation of hCSD1
Recombinant protein expression was performed in 2 L baﬄed ﬂasks
containing 1 L LB (Duchefa) while shaking at 180 rpm at 37 °C in a
minitron orbital shaker-incubator (InFors HT). Before the inoculation,
D-biotin (Sigma) was added to the media to the ﬁnal concentration of
50 μg/mL. For the pT7pol23 containing cells, the culture temperature
was raised to 42 °C for 1 h when the OD600 reached 0.4 and subse-
quently reduced to 37 °C prior to the addition of 1mM isopropyl-β-D-1-
thiogalactopyranoside (IPTG). For the pT7pol26 containing cells, 0.4%
L-arabinose was added to the culture at OD600 of 0.4, prior to induction
with 1mM IPTG when the OD600 reached 0.6. The cell cultures were
collected after 5 h of induced protein expression. The collected cell
cultures were centrifuged at 5000 g for 15min, the supernatants were
discarded and the cell pellets were stored at -20 °C.
For the 15N-isotope labelling of hCSD1 and avi-hCSD1, the E. coli
BL21-AI and BL21(DE3) strains that contained the corresponding
plasmids were grown in M9 minimal medium (1 L contained 6.0 g
Na2HPO4, 3.0 g KH2PO4, 0.5 g NaCl, 1.0 g15NH4Cl, 1 mM MgSO4,
0.6 mM CaCl2, 1mg/L D-biotin, 1 mg/L thiamine and supplemented
with the required antibiotics) using 15N-isotope NH4Cl as the sole ni-
trogen source (Cambridge Isotopes Laboratories). As carbon source we
added 0.2% D-glucose for E. coli BL21(DE3)) or 0.2% glycerol for E. coli
BL21-AI to the minimal medium. The cells were grown at 37 °C as de-
scribed earlier and protein expression was induced with 1mM IPTG at
OD600 of 0.6. The cell cultures were collected after 5 h of induction.
2.3. Protein puriﬁcation procedures
2.3.1. Puriﬁcation of various hCSD1 constructs
The hCSD1-containing cell pellets (i.e. untagged hCSD1, avi-hCSD1
and b-avi-hCSD1) were resuspended in a 50mM Tris-HCl pH 7.5 buﬀer
containing 0.1 mM ethylenediaminetetraacetic acid (EDTA), 2 mM di-
thiothreitol (DTT) and protease inhibitor cocktail (Roche tablets), fol-
lowed by heating at 90 °C for 15min in a ThermoScientiﬁc water-bath.
The lysates were centrifuged at 21119 g for 30min. After ﬁltering the
cleared lysates through a 0.2 μm cut-oﬀ polyethersulfone membrane
(Sarstedt), the samples were kept on ice and all subsequent protein
puriﬁcation steps were performed at 4 °C. The sample was applied to a
5mL HiTrap DEAE anion exchange column (GE Healthcare) equili-
brated with 50mM Tris-HCl, 0.1 mM EDTA, 2mM DTT pH 7.5 and the
protein was eluted with a step elution of 150mM NaCl [7]. Depending
on the sample purity an optional size exclusion chromatography was
performed using a Superdex 75 10/30 GL (GE Healthcare) in 20mM 3-
(N-morpholino)propanesulfonic acid (MOPS), 1 mM Tris(2-carbox-
yethyl)phosphine (TCEP) pH 7.5.
2.3.2. Aﬃnity puriﬁcation of human m-calpain with in vivo biotinylation
hCSD1
The lysate containing in vivo biotinylated avi-tagged hCSD1 (b-avi-
hCSD1) and the puriﬁed b-avi-hCSD1 was loaded into a HiTrap
Streptavidin HP 1ml column (GE Healthcare) equilibrated with the
binding buﬀer MOPS pH 7.5, 1 mM TCEP and 150mM NaCl) supple-
mented with 5mM CaCl2. The column was washed with 5 column vo-
lumes of the same binding buﬀer, followed by loading the C105A-cal-
pain lysate supplemented with 5mM CaCl2 to the column. The calpain
was eluted from the b-avi-hCSD1-containing resin by applying 10mM
EDTA (in binding buﬀer).
2.4. In vitro chemical biotinylation of hCSD1
The chemical biotinylation of hCSD1 was accomplished using EZ-
Link™ NHS-PEG4-Biotinylation kit (Pierce Biotechnology) according to
the manufacturer's instructions and as described previously [7]. The
extent of the biotinylation was determined by a colorimetric quantiﬁ-
cation kit provided by the same manufacturer (Pierce Biotechnology)
utilizing the absorbance-based 2-(4′-hydroxyazobenzene) benzoic acid
(HABA) dye.
2.5. Electrophoresis and western blotting
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) was run using 12.5% polyacrylamide gel with a PageRuler™ pre-
stained protein ladder (ThermoFisher Scientiﬁc) in Tris-glycine buﬀer
at 200 V for 40min. To directly visualize all the proteins, the gel was
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stained using PageBlue™ staining solution (ThermoFisher Scientiﬁc).
After performing SDS-PAGE, the gel was transferred to a 0.2 μm
polyvinylidene ﬂuoride (PVDF) membrane using Trans-blot Turbo
blotting system (Bio-Rad) at 1.3 A for 14min. The transferred mem-
brane was blocked with phosphate-buﬀered saline (PBS) containing
0.1% Tween-20 and 5% non-fat dried milk for 30min, followed by
incubating with horseradish peroxidase (HRP)-conjugated streptavidin
(ThermoFisher Scientiﬁc) at a 1:10000 dilution, on a vertical rotator for
2 h at room temperature. The membrane was further rinsed three times
with PBS, and washed two times with PBS supplemented with 0.1%
Tween-20 for 20min each. The membrane was incubated with Pierce
ECL Western blotting substrate for 2min after visualization using Image
Lab software with ChemiDoc XRS System (Bio-Rad).
2.6. Mass spectrometry sample preparation and analysis
2.6.1. Protein intact mass analysis
The four proteins that were analyzed (hCSD1, (chemically biotiny-
lated) b-hCSD1, avi-hCSD1 and (in vivo biotinylated) b-avi-hCSD1) were
solubilized in 0.5% TFA, desalted on ZipTip C18 (Millipore) and eluted
in 5 μL 50% acetonitrile/1% formic acid (v/v). The samples were
loaded into a nanoﬂow capillary (Thermo Fisher Scientiﬁc). Electron
spray ionisation (ESI) mass spectra were acquired on a quadrupole
time-of-ﬂight instrument (Q-Tof Ultima –Waters/Micromass) operating
in the positive ion mode, equipped with a Z-spray nanoelectrospray
source. Data acquisition was performed using a MassLynx 4.1 system.
The spectra were recorded in the V mode and represented the combi-
nation of 1 s scans. The molecular mass of the proteins was determined
after processing of the raw data with the software MaxEnt1.
2.6.2. Peptide microsequencing
The protein bands were excised from the SDS-PAGE gel and crushed
in small pieces of about 1mm3. The gel pieces were washed with 25mM
NH4HCO3 and 50% CH3CN/25mM NH4HCO3 and then dried in a va-
cuum centrifuge. The gel pieces were swollen in an ice-cold bath in
10 μL of a digestion buﬀer containing 25mM NH4HCO3, and 10 ng/μL
of sequencing grade modiﬁed trypsin (Promega) or Endoproteinase Glu-
C (Promega). The digestion was carried out overnight at 37 °C. The
supernatant was collected and the peptides remaining in the gel pieces
were extracted sequentially by 25mM NH4HCO3, 50% CH3CN/25mM
NH4HCO3 and 50% CH3CN/5% HCOOH. The supernatant and the wash
were pooled and dried in a vacuum centrifuge. The sample hCSD1 was
also digested in solution overnight at 37 °C with sequencing grade
Endoproteinase Glu-C (protein/enzyme mass ratio 25:1).
Before analysis by mass spectrometry, the sample was desalted on
ZipTip C18 (Millipore) and eluted in acetonitrile 50%/formic acid 1%
(v/v). The samples were loaded into a nanoﬂow capillary (Proxeon) and
ESI mass spectra were acquired on a quadrupole time-of-ﬂight instru-
ment (Q-Tof Ultima - Waters/Micromass) operating in the positive ion
mode, equipped with a Z-spray nanoelectrospray source. The tryptic
peptides were analyzed by tandem mass spectrometry (MS/MS). After
processing of the MS/MS data by the maximum entropy data en-
hancement program MaxEnt 3, the amino acid sequences were semi-
automatically deduced using the peptide sequencing program PepSeq
(Waters, Milford, USA). Based on the peptide sequences, the proteins
were identiﬁed using the MASCOT Sequence Query.
2.7. Biophysical characterization
2.7.1. Nuclear magnetic resonance analysis
The 1H-15N-transverse relaxation-optimized spectroscopy (TROSY)
spectra of 0.2mM hCSD1 or 0.44mM avi-hCSD1 constructs were re-
corded at 25 °C in 20mM MOPS pH 7.5, 1 mM TCEP, and 10% D2O
(Sigma) for the lock. The experiments were acquired on an 800MHz
Bruker NMR spectrometer equipped with TCI cryoprobe for enhanced
sensitivity and processed in TopSpin v3.2.
2.7.2. Bio-layer interferometry
The b-hCSD1 and b-avi-hCSD1 at a concentration of 2.5 and 50 μg/
mL, respectively, were immobilized with a similar BLI intensity onto SA
biosensors (ForteBio) that contain covalently attached streptavidin. The
buﬀer consisted of 20mM MOPS pH 7.5, 5 mM CaCl2, 0.1% Tween-20
and 0.1% bovine serum albumin (BSA), which was used to minimize the
non-speciﬁc interaction of calpain with the biosensors. A calpain con-
centration range from 60 nM to 500 nM was used during the association
phase. Each of those concentrations had its corresponding non-func-
tionalized biosensor as a parallel reference sensor. The binding data
were recorded at 25 °C with agitation at 1000 rpm using the ForteBio
data acquisition software v9.0. The ﬁtting of individual binding curves
was done using ForteBio data analysis software v9.0. The steady state
analysis was analyzed in Graphpad Prism 7 using non-linear regression
with the equation Y = Bmax*X/(KD + X), where Bmax is the maximum
speciﬁc binding, and KD represents the equilibrium dissociation con-
stant.
2.7.3. Homology modelling
The human homology model was generated with the SwissModel
server (https://swissmodel.expasy.org/) using 3DF0.pdb as structural
template and UNIPROT codes P17655, P04632 and P20810 as se-
quences for CAPN2, CAPNS1 and calpastatin region 137-277 (i.e.
hCSD1), respectively [13]. The ﬁgures were generated with Pymol (The
PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC).
3. Results and discussion
3.1. In vivo biotinylation of avi-hCSD1 and puriﬁcation of diﬀerent hCSD1
variants
Since the hCSD1 sequence has no natural BAP-sequence [14], we
generated an avi-tagged hCSD1 construct (avi-hCSD1) so that in vivo
biotinylation would occur only speciﬁcally at the N-terminal avi-tag
lysine site. Therefore, we tested diﬀerent expression strategies to es-
tablish an in vivo biotinylation protocol for avi-hCSD1. Since the re-
combinant overexpression of hCSD1 was reported to be successful with
inducible T7 promoter plasmids, we opted for a pET22 plasmid to
produce the avi-hCSD1 in E. coli [7,15]. Because the two commercially
available E. coli strains (AVB100 and AVB101) that enable in vivo bio-
tinylation do not contain the T7 RNA polymerase, we tested 2 plasmids
(pT7pol23 and pT7pol26) that carry an inducible T7 RNA polymerase
gene for its applicability in our production strategy [12]. The results of
the SDS-PAGE and Western blotting analysis of these expression tests
are depicted in Fig. 1.
Even though, the expression of the in vivo biotinylated avi-hCSD1
(represented as b-avi-hCSD1) was not clearly observable through the
appearance of one additional prominent protein band via SDS-PAGE
(Fig. 1A), the Western blotting analysis of the same gel showed that the
in vivo biotinylated form of the protein expressed well in all combina-
tions of plasmids and E. coli strains (Fig. 1B). Upon comparing the
pT7pol23 and pT7pol26 plasmids, we noticed that the cells containing
pT7pol23 displayed a more pronounced leaky expression of b-avi-
hCSD1 prior to induction with IPTG as compared to the pT7pol26
construct. This observation can be rationalized by the fact that
pT7pol23 contains a thermally inducible promoter that is not tightly
controlled at 30 °C. Thus, this protocol can probably be optimized by
reducing the growth temperature from 37 °C to 28 °C (or lower) prior to
shifting it to 42 °C to induce expression [16].
From the Western blotting it also becomes clear that the anticipated
endogenously biotinylated BCCP protein was present in the induced
sample (albeit at variable quantities), as its band runs at the expected
molecular mass of 16.7 kDa (Fig. 1B). In the AVB101 strain, another
(unexpected) biotinylated contaminant was observed around 35 kDa.
Based on those observations, we have selected the combination of the E.
coli AVB100 strain and the pT7pol26 plasmid for further puriﬁcation as
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it had a good level of b-avi-hCSD1 expression and less contaminating
biotinylated proteins. Since it was also reported that BirA would be less
soluble at elevated temperatures, we preferentially opted for the
pT7pol26-based expression system whereby the fermentation tem-
perature is kept constant [17].
With E. coli AVB100 that contains the pAvihCSD1 and pT7pol26
plasmids we scaled up the production of b-avi-hCSD1 (in vivo biotiny-
lated avi-hCSD1). After the heat treatment of the resuspended cells, b-
avi-hCSD1 was isolated from the cleared lysate by an anion exchange
chromatography and a polishing size exclusion chromatography
(Fig. 2). During this procedure, we observed the presence of a heat-
resistant contaminating protein, which we further identiﬁed by MS/MS
peptide microsequencing as ﬂagellin. We found that ﬂagellin can be
separated from b-avi-hCSD1 by size exclusion chromatography using a
Superdex 75 10/30 GL column (Fig. 2B and C). Although the presence
of ﬂagellin would not aﬀect our downstream calpain puriﬁcation
strategy (see section 3.5) as it does not bind to the streptavidin column
and is located in the ﬂow-through (Fig. 7 - lane 2), we have also tried to
apply the commercial detergent-based BugBuster® protein extraction
reagent (Novagen) as an alternative lysis method in an attempt to re-
move ﬂagellin, without success.
The puriﬁcation of the untagged version of hCSD1 and its in vitro
chemical biotinylation (resulting in b-hCSD1) allowed for further
functional and comparative studies with the b-avi-hCSD1. In this con-
text, we can also report that the production of 15N-isotope labelled
hCSD1 and avi-hCSD1 through bacterial expression in minimal medium
and its subsequent puriﬁcation did not reveal any additional experi-
mental obstacles e.g. degradation or presence of contaminants …).
3.2. Mass spectrometry analysis of hCSD1 and avi-hCSD1 biotinylation
We conﬁrmed by ESI MS analysis that the experimental molecular
mass of puriﬁed b-avi-hCSD1 (17047 Da) was increased with a shift of
mass of 226 Da as compared to avi-hCSD1 (experimental molecular
mass of 16821 Da). This corresponds to the addition of a single D-biotin
molecule to the protein by the BirA biotin-protein ligase. By MS/MS
peptide microsequencing and the direct comparison of avi-hCSD1 and
b-avi-hCSD1 peptides, we further conﬁrmed that the only site of bio-
tinylation is indeed the ﬁrst lysine in the sequence, which is located
within the avi-tag. This experimental result also reveals that the heat
treatment that is typically employed for the puriﬁcation of IDPs does
not alter the integrity of the protein and doesn't lead to any further
chemical modiﬁcations.
With regard to the chemical (in vitro) biotinylation, by combining
peptide mass ﬁngerprinting and MS/MS peptide microsequencing we
could determine that most of the lysine residues in b-hCSD1 were
biotinylated. For each detected digested peptide that contains one or
two lysine residues, we observed a 473 Da or 946 Da shift of its ex-
perimental molecular mass, respectively. This is in perfect agreement
with the expected mass of 473.22 Da that is added to the target lysine
by the reaction with NHS-PEG4-biotin, which is a PEGylated and
amine-reactive variant of D-biotin. We could detect the appearance of
biotinylated peptides that cover 10 out of 13 lysine residues in the
Fig. 1. Recombinant expression analysis of in vivo biotinylated avi-tagged hCSD1 (b-avi-hCSD1) based on (A) SDS-PAGE with Coomassie staining and (B) Western blotting
with HRP-conjugated streptavidin. The diﬀerent combinations of E. coli strains (the E. coli K12-derived AVB100 and the E. coli B-based AVB101) that contain the pAvihCSD1 plasmid
and either pT7pol23 or pT7pol26, are indicated at the top of the image. NI represents the non-induced cells, while I represents the sample of the cells at 4 h after the induction of protein
expression. The proteins of interest are indicated with an arrow and the molecular weight (in kDa) of the marker proteins is indicated on the left hand side of the images.
Fig. 2. SDS-PAGE analysis with Coomassie staining of (A) the anion exchange
chromatography and (B) the gelﬁltration elution fractions of b-avi-hCSD1, which
are corresponding to (C) the gelﬁltration elution proﬁle. 1: lysate of E. coli AVB100
containing pT7pol26 and pAvihCSD1, after heat treatment and clearance by centrifuga-
tion; 2: ﬂow-through; 3: elution fraction at 150mM NaCl; Panel B represents the gelﬁl-
tration elution fractions for avi-hCSD1 whereby the numbering corresponds to the elution
fractions of the chromatogram that is depicted in Panel C.
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hCSD1 sequence. Also the concomitant disappearance of the corre-
sponding unmodiﬁed peptides was monitored. Unfortunately, in this
way, it was not possible to detect the N-terminal peptide comprising
residues 1-38 from hCSD1, which contains 3 lysines. The undetect-
ability of this peptide (in both hCSD1 and b-hCSD1) is likely due to its
large size (theoretical molecular mass of 3959.32 Da for the non-bio-
tinylated peptide). However, we could compare the experimental mo-
lecular mass of the intact unmodiﬁed hCSD1 of 14764 Da (in perfect
accord with the expected theoretical mass of 14764.28 Da) to the total
experimental mass of b-hCSD1 that was 21018 Da. Under the assump-
tion that the 13 lysines in the polypeptide are biotinylated, we expected
a molecular mass of 20913 Da (i.e. 14764 + (13 × 473) = 20913 Da).
Thus, from the mass spectrometry analysis it is plausible to conclude
that the 13 lysines are biotinylated, while an extra mass of 105 Da is
present. The nature of this additional 105 Da, likely a posttranslational
modiﬁcation, remains enigmatic. Yet, we can rule out that this (post-
translational) modiﬁcation occurs during the boiling of the cell re-
suspension since both avi-hCSD1 and hCSD1 had the expected and
correct experimental mass. Hence, some additional modiﬁcation should
have occurred only during (or after) the chemical biotinylation reac-
tion. Nevertheless, since we detected the correct masses for all digested
peptides except the N-terminal 38-residues long peptide, the mod-
iﬁcation can only be present in this segment.
With this approach combining molecular mass determination, pep-
tide mass ﬁngerprinting and MS/MS microsequencing, we suggested
that all lysine positions in b-hCSD1 have been biotinylated (even
identiﬁed at a residue-level). This was somewhat surprising based on
the result of the HABA-based colorimetric quantiﬁcation method where
on average only 8 biotin molecules were attached per hCSD1 molecule.
In our previous study, we reported based on this colorimetric assay that
the chemical biotinylation of hCSD1 (i.e. b-hCSD1) yielded 2mol biotin
per mol of hCSD1 [7]. While this could point to the rather non-speciﬁc
nature of the chemical biotinylation and the possible batch-to-batch
dependence, this discrepancy might also be explained through the in-
accuracy of determining the concentrations of IDPs [18].
Nonetheless, this analysis conﬁrms that the in vivo biotinylation
strategy allowed us to strictly control the extent and position in the
sequence of the biotin addition, in contrast to the in vitro biotinylation
that yields a multi-biotinylated protein.
3.3. Eﬀect of the avi-tag on the structural properties of hCSD1 using NMR
We also examined if the avi-tag would interfere with the IDP nature
of hCSD1. Therefore, we collected a 1H-15N transverse relaxation-op-
timized spectroscopy (TROSY) of the avi-tagged hCSD1 and compared it
to the spectrum of its untagged counterpart (Fig. 3). The TROSY spec-
trum displays the low dispersion in the proton dimension that is typical
for an intrinsically disordered protein [19,20]. We could observe a
number of additional signals in the avi-hCSD1 spectrum, which agrees
with the presence of 18 additional residues in the avi-tagged construct
as compared to the untagged hCSD1. This also includes the appearance
of a Trp indole resonance at 10 ppm δH that is uniquely present in the
avi-tag (Fig. 3). Since the chemical shift is very sensitive to the chemical
environment, for instance due to structural changes, we conclude from
this dataset that the mere presence of the N-terminal avi-tag does not
interfere with the IDP nature of hCSD1.
3.4. Eﬀect of the biotinylation of hSCD1 on its binding properties
Since our mass spectrometry results revealed that chemical bioti-
nylation lead to the modiﬁcation of multiple lysines in hCSD1, we ex-
pected that the subsequent streptavidin-based immobilization of b-
hCSD1 could display a reduced functionality in binding to its calpain
substrate. With the b-avi-hCSD1, we anticipated that the full function-
ality of hCSD1 would be retained. Therefore, the eﬀect of the biotiny-
lation method on the binding properties of hCSD1 to calpain was
analyzed using bio-layer interferometry (BLI). This BLI analysis relied
on the immobilization of the biotinylated hCSD1 variants to the bio-
sensor surface with subsequent exposure to various concentrations of
m-calpain, whereby the association and dissociation phases were re-
corded. With this strategy, we could detect the concentration-depen-
dent binding of m-calpain to both hCSD1 variants in real time (Fig. 4).
The binding curves of b-avi-hCSD1 suggested that a simple 1:1 binding
occurred, as the experimental data could be ﬁtted with this model
(Fig. 4A). For the immobilized b-hCSD1, the simple 1:1 model could not
be applied to ﬁt the data, whereas the heterogeneous binding model
gave the best ﬁtting results (Fig. 4B). This conﬁrmed, while b-avi-
hCSD1 displayed a homogeneous binding behavior to m-calpain, that
the chemical biotinylation in the case of b-hCSD1 has led to an intrinsic
sample heterogeneity. The aﬃnity constant of the interaction of b-avi-
hCSD1 to calpain (73.1 nM) derived from the steady state analysis was
two times lower that of b-hCSD1 (134.4 nM) (Fig. 4C and D and
Table 1). In addition to this apparent higher aﬃnity, the association
rate of calpain to b-avi-hCSD1 was also almost four times faster com-
pared to b-hCSD1 (Table 1). These are likely explained as the result of
the simultaneous biotinylation of multiple lysine residues along the
hCSD1 sequence. This in vitro biotinylation might not only interfere
with its ﬂexibility when being immobilized onto the streptavidin bio-
sensors, it could also reduce its overall binding capacity to calpain (as
reﬂected in the reduced signal-to-noise for b-hCSD1 curves as compared
to b-avi-hCSD1). The exact modus operandi of hCSD1 binding to the
calcium-activated m-calpain surface was revealed when the crystal
structures of the bound rat proteins were solved (Fig. 5A) [21,22]. The
intrinsically disordered hCSD1 and its rat counterpart encompassed
three segments that became structured upon binding: regions A and C
form an alpha-helical element, while the extended region B actually
covered the active site cleft of m-calpain (Fig. 6). Based on the x-ray
structure (3DF0.pdb) we generated a homology model for the human
complex of hCSD1 and m-calpain to visualize the position of the lysine
residues in the visible structure (Fig. 5B) (supplementary material).
These lysines are distributed along the sequence and 5 lysines (depicted
in the spherical representation in orange in Fig. 5B) are actually mod-
elled in the visible regions of hCSD1. It is therefore conceivable that
upon biotinylating these lysines, the proper binding of b-hCSD1 to the
calpain surface gets aﬀected.
These results provide a strong evidence that biotinylation of hCSD1
speciﬁcally and perhaps IDPs in general, through an avi-tag is not only
more convenient but also better since it preserves their (un)structured
and fully functional state.
Fig. 3. Overlay of the 1H-15N transverse relaxation-optimized spectroscopy of hCSD1
(black) and avi-hCSD1 (Red). (For interpretation of the references to color in this ﬁgure
legend, the reader is referred to the Web version of this article.)
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3.5. Aﬃnity puriﬁcation of human m-calpain based on in vivo biotinylated
hCSD1
Since we successfully applied an in vivo biotinylation strategy and
veriﬁed the functionality of the avi-hCSD1 in its binding to m-calpain,
we wanted to implement the b-avi-hCSD1 in an aﬃnity chromato-
graphy to purify its calpain substrate. Our previously published aﬃnity
puriﬁcation method for calpain was based on b-hCSD1 and required the
separate puriﬁcation of hCSD1 and its subsequent chemical biotinyla-
tion (Fig. 6) [7]. With the in vivo biotinylated b-avi-hCSD1 we en-
visaged that we could omit the requirement for calpastatin isolation
and in vitro biotinylation and directly load the b-avi-hCSD1 containing
lysate onto the straptavidin-based resin.
By applying a b-avi-hCSD1-containing lysate directly to the strep-
tavidin-containing resin, followed by the cleared lysate that contains
the calcium-bound inactive C105A m-calpain and ﬁnally the elution of
calpain by applying EDTA to the resin, the yield of the calpain pur-
iﬁcation was increased by two times as compared to applying chemi-
cally biotinylated hCSD1 (b-hCSD1). From 1 L LB in which E. coli
BL21(DE3) expresses the heterodimeric and inactive C105A mutant m-
calpain we obtained 2mg upon this new puriﬁcation strategy, while the
purity is retained at the same level as described before (Fig. 7) [7]. This
is probably due to the fact that the in vivo biotinylation occurs speci-
ﬁcally (and solely) at the N-terminus, thus allowing a more eﬃcient and
functional immobilization of hCSD1. The multi-biotinylated b-hCSD1
(13 biotin molecules along the 140-residue-long polypeptide according
to our mass spectrometry data) can probably occupy multiple strepta-
vidin sites, thereby (1) causing heterogeneity in its binding behavior
(less available binding motifs) or (2) reducing the total number of b-
hCSD1 that can be immobilized to the column. The single-biotinylated
b-avi-hCSD1 is likely to retain its full capacity to capture m-calpain
from biological mixture (see section 3.4) and likely also obtains a more
uniform and higher loading density on the resin. In addition to the
increased yield, this strategy also entails less hands-on time, less ma-
terials and consumables and less energy since there is no need for prior
puriﬁcation of hCSD1 that requires chemical biotinylation. Despite
having observed the heat-resistant ﬂagellin and the biotinylated BCCP
during the development of this strategy, both contaminants where not
observed in the ﬁnal sample (Fig. 7). Therefore, we can conclude that
the combination of in vivo biotinylation of hCSD1 with the single-
chromatographic-step puriﬁcation of m-calpain constitutes a real im-
provement of the original puriﬁcation strategy (Fig. 6).
4. Conclusion and future perspectives
We presented a novel and improved method to isolate m-calpain
based on calpastatin, whereby we have optimized our protein produc-
tion workﬂow at the cloning (with a new tag), expression (co-trans-
formation with pT7pol26 and co-expression of BirA) and puriﬁcation
level (single-resin aﬃnity puriﬁcation). The introduction of an avi-tag
at the N-terminus of hCSD1 allowed for the speciﬁc in vivo biotinylation
in an E. coli expression system. We characterized the avi-hCSD1 at the
Fig. 4. Biolayer interferometry was used to monitor the binding kinetics (A and B) and steady-state analysis (C and D) of the interaction between immobilized b-avi-hCSD1 (A and C) or b-
hCSD1 (B and D) and calcium-bound m-calpain in solution at various concentrations.
Table 1
Binding kinetics analysis parameters of the calpain-calpastatin interaction.
b-avi-hCSD1 b-hCSD1
KD (nM) kon (M−1.s−1.104) koﬀ (s−1.10−3) KD (nM) kon (M−1.s−1.104) koﬀ (s−1.10−3)
73.1 ± 0.3 11.6 ± 0.1 8.5 ± 0.1 134.4 ± 0.8 3.2 ± 0.1 4.4 ± 0.2
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Fig. 5. Representation of the crystal structure (A)
of the rat m-calpain structure in complex with the
rat calpastatin domain (3DF0.pdb)) and the
homology model (B) of the human m-calpain
bound to hCSD1 (in cartoon representation). The
heterodimeric m-calpain is depicted with the surface
representation (rat in green, human in blue), the cal-
pastatin domains are shown in the cartoon re-
presentation (pink or yellow) and the lysine residues in
the visible calpastatin domains are highlighted in the
sphere representation. The large subunits (corre-
sponding to CAPN2) are represented in the dark color;
the small subunits (corresponding to CAPNS1) are re-
presented in the lighter color. (For interpretation of the
references to color in this ﬁgure legend, the reader is
referred to the Web version of this article.)
Fig. 6. Schematic comparison of the various steps and procedures needed for the aﬃnity puriﬁcation of human m-calpain based on biotinylated versions of hCSD1. Our
original aﬃnity puriﬁcation methodology was based on the recombinant expression of hCSD1, followed by a heating step (95 °C for 10min) and clearance of insoluble material via
centrifugation [7]. This sample was then puriﬁed by anion exchange chromatography (eluted with NaCl) and subjected to an in vitro chemical biotinylation protocol using a commercially
available kit. The resulting b-hCSD1 was then immobilized onto a streptavidin-based resin and used to capture recombinantly produced human m-calpain from the bacterial lysate
(sonicated, centrifuged and supplemented with calcium). The complex between calpain and b-hCSD1 was dissociated by applying EDTA as a third step onto the column, leading to the
elution of calpain. Our novel and improved method is based on the co-expression of avi-tagged hCSD1 and the biotin-ligase BirA that covalently attaches biotin to avi-hCSD1. The b-avi-
hCSD1 is compatible with heat treatment for IDP puriﬁcation and can be immobilized directly onto the streptavidin-based resin without the need for any additional manipulation. The
subsequent workﬂow for calpain aﬃnity puriﬁcation is the same as the original method, but leads to an increased protein yield.
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residue level by combining NMR, BLI and MS analysis and found that
(1) only the avi-tag is modiﬁed with biotin, (2) the presence of the avi-
tag does not interfere with the intrinsically disordered nature of hCSD1,
and (3) its binding potential to the calcium-activated calpain surface is
improved. Hence, this approach enabled the direct puriﬁcation/im-
mobilization of b-avi-hCSD1 on streptavidin-based resin without the
need of any additional prepuriﬁcation step. With this new workﬂow to
ultimately purify m-calpain based on its reversible binding of calcium
and calpastatin, not only have we reduced considerably the puriﬁcation
time, but we also reduced the required energy, materials and consum-
ables (and concomitantly the production cost per puriﬁed sample),
which is important in these times of growing ecological awareness and
sustainability (Fig. 6).
To the best of our knowledge this is the ﬁrst time that an in vivo
biotinylation protocol for an IDP (and its puriﬁcation based on heat-
treatment of resuspended cells) is reported. Since it is a cost-eﬀective
and a considerably simpliﬁed protocol that can be routinely used to
purify any protein of interest through reversible binding onto the
column, it seems particularly convenient to use with IDPs. Biotinylation
might also be carried out in vitro with puriﬁed avi-tagged IDPs and
puriﬁed BirA as this is reported to be easily produced at large scale
[17]. Apart from the applicability of biotinylation for immobilization, it
can be used as a detection method for various biological assays em-
ploying avidin/streptavidin-conjugated antibody or biotin-conjugated
dye.
In conclusion, we described a successful and easily-applicable pro-
tein expression and aﬃnity-capture strategy by combining commer-
cially accessible plasmids and commercial E. coli strains. This new
strategy not only facilitated the scale-up of calpain puriﬁcation in
particular, but also advocated for the general applicability of in vivo
biotinylated IDPs in aﬃnity puriﬁcation strategies.
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Fig. 7. Aﬃnity puriﬁcation with streptavidin-loaded resin of the C105A mutant of
human m-calpain using b-avi-hCSD1-containing lysate after heat treatment. M:
Marker proteins with their corresponding molecular weight (in kDa) indicated on the left;
Lane 1: b-avi-hCSD1 lysate after heat treatment and centrifugation; Lane 2: ﬂow-through
when b-avi-hCSD1 lysate was loaded onto the streptavidin-loaded resin; Lane 3: bacterial
lysate that contains human m-calpain; Lane 4: ﬂow-through when calcium-activated
calpain-containing lysate was loaded; Lane 5: when the column was eluted with EDTA,
the elution fraction contained predominantly the large (CAPN2) and small (CAPNS1ΔG2)
subunits of m-calpain.
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